Literature DB >> 23807777

Reproducibility of histological cell type in high-grade endometrial carcinoma.

Guangming Han1, Davinder Sidhu, Máire A Duggan, Jocelyne Arseneau, Matthew Cesari, Philip B Clement, Carol A Ewanowich, Steve E Kalloger, Martin Köbel.   

Abstract

Subclassification of endometrial carcinoma according to histological type shows variable interobserver agreement. The aim of this study was to assess specifically the interobserver agreement of histological type in high-grade endometrial carcinomas, recorded by gynecological pathologists from five academic centers across Canada. In a secondary aim, the agreement of consensus diagnosis with immunohistochemical marker combinations was assessed including six routine (TP53, CDKN2A (p16), ER, PGR, Ki67, and VIM) and six experimental immunohistochemical markers (PTEN, ARID1A, CTNNB1, IGF2BP3, HNF1B, and TFF3). The paired interobserver agreement ranged from κ 0.50 to 0.63 (median 0.58) and the intraobserver agreement from κ 0.49 to 0.67 (median 0.61). Consensus about histological type based on morphological assessment was reached in 72% of high-grade endometrial carcinomas. A seven-marker immunohistochemical panel differentiated FIGO grade 3 endometrioid from serous carcinoma with a 100% concordance rate compared with the consensus diagnosis. More practically, a three-marker panel including TP53, ER, and CDKN2A (p16) can aid in the differential diagnosis of FIGO grade 3 endometrioid from endometrial serous carcinoma. Our study demonstrates that the inter- and intraobserver reproducibility of histological type based on morphology alone are mostly moderate. Ancillary techniques such as immunohistochemical marker panels are likely needed to improve diagnostic reproducibility of histological types within high-grade endometrial carcinomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23807777     DOI: 10.1038/modpathol.2013.102

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  45 in total

1.  Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Authors:  Carlos Parra-Herran; Jordan Lerner-Ellis; Bin Xu; Sam Khalouei; Dina Bassiouny; Matthew Cesari; Nadia Ismiil; Sharon Nofech-Mozes
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.

Authors:  Oluwole Fadare; Vinita Parkash; Katja Gwin; Krisztina Z Hanley; Elke A Jarboe; Sharon X Liang; Charles M Quick; Wenxin Zheng; Kojo R Rawish; Jonathan L Hecht; Mohamed M Desouki
Journal:  Hum Pathol       Date:  2013-10-10       Impact factor: 3.466

Review 3.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

Review 4.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

5.  Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

Authors:  Matthieu Le Gallo; Meghan L Rudd; Mary Ellen Urick; Nancy F Hansen; Suiyuan Zhang; Fred Lozy; Dennis C Sgroi; August Vidal Bel; Xavier Matias-Guiu; Russell R Broaddus; Karen H Lu; Douglas A Levine; David G Mutch; Paul J Goodfellow; Helga B Salvesen; James C Mullikin; Daphne W Bell
Journal:  Cancer       Date:  2017-05-09       Impact factor: 6.860

6.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Authors:  Martin Köbel; Bo Meng; Lien N Hoang; Noorah Almadani; Xiaodong Li; Robert A Soslow; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma.

Authors:  Sumi Thomas; Yaser Hussein; Sudeshna Bandyopadhyay; Michele Cote; Oudai Hassan; Eman Abdulfatah; Baraa Alosh; Hui Guan; Robert A Soslow; Rouba Ali-Fehmi
Journal:  Arch Pathol Lab Med       Date:  2016-05-03       Impact factor: 5.534

8.  Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort.

Authors:  Marie Boennelycke; Elke E M Peters; Alicia Léon-Castillo; Vincent T H B M Smit; Tjalling Bosse; Ib Jarle Christensen; Gitte Ørtoft; Claus Høgdall; Estrid Høgdall
Journal:  Virchows Arch       Date:  2021-06-11       Impact factor: 4.064

9.  Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.

Authors:  Salwa Bakhsh; Mary Kinloch; Lien N Hoang; Robert A Soslow; Martin Köbel; Cheng-Han Lee; Jessica N McAlpine; Melissa K McConechy; C Blake Gilks
Journal:  Histopathology       Date:  2015-12-17       Impact factor: 5.087

10.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

Authors:  Aline Talhouk; Lien N Hoang; Melissa K McConechy; Quentin Nakonechny; Joyce Leo; Angela Cheng; Samuel Leung; Winnie Yang; Amy Lum; Martin Köbel; Cheng-Han Lee; Robert A Soslow; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Gynecol Oncol       Date:  2016-07-14       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.